Skip to main content
OpenTrials
Completed

NCT Number: NCT01167829

ORAL T-8 Oral Testosterone for Male Hormonal Contraception

The purpose of this study is to test how the body absorbs a new form of oral testosterone (T). On Day 1 and Day 9 there are overnight stays in the General Clinical Research Center at the University of Washington to monitor blood testosterone levels over a 24-hour period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

University of Washington

Seattle, Washington, 98195, United States

About this study

We will administer two experimental drugs, acyline and oral testosterone. Acyline shots will be given on Day 0 to turn off the body's testosterone production for about 10-14 days.

The next day, Day 1, subjects begin taking 300 mg modified slow-release testosterone pill by mouth, three times a day, around 9 AM, 1 PM, and 7 PM for a total of 27 pills.

There are overnight stays on Day 1 and Day 9 to allow monitoring of blood testosterone levels over a 24 hour period, from @9 AM to 9 AM the next morning. At those visits, blood is drawn at baseline (before taking the pill) and at 1, 2, 4, 5, 6, 8, 10, 11, 12, 14, 16, and 24 hours after the morning dose.

Acyline is an experimental drug. The FDA allows its use only in research with a small number of volunteers. We have used acyline in over 125 men without serious side effects. The use of testosterone in this study is experimental and there may be unknown or unanticipated risks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • able and willing to
  • not participate in another drug study or donate blood, not take medications
  • use contraception, comply with the protocol

Exclusion criteria

  • abnormal evaluation, based on physical exam, medical history, blood tests (including serum chemistry, hematology, HIV, HCV, hormone levels)
  • history or current use of alcohol, drug, steroid abuse, >3 alcohol drinks/day
  • history of testicular disease, severe testicular trauma, major psychiatric disorder, bleeding disorders, current use of anti-coagulants or testosterone
  • participation in hormonal drug study within past month

Treatment and study plan

Oral Testosterone

Drug

Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)

Acyline

Drug

300 ug/kg injection on Day 0

Primary outcomes

  1. Maximum Testosterone Concentration

    Time frame: baseline & day 9

    initial pharmacokinetics [PK] (day 1) of oral testosterone dosed 3 times daily and the PK after 9 days of treatment

  2. Mean Testosterone Concentration

    Time frame: baseline & day 9

    initial 24-hour pharmacokinetics (PK) of oral testosterone dosed 3 times daily and post 24-hour PK after 9 days of treatment

Secondary outcomes

  1. Maximum Dihydrotestosterone (DHT) Concentration

    Time frame: baseline & day 9

  2. Mean Dihydrotestosterone (DHT) Concentration

    Time frame: baseline & day 9

  3. Maximum Sex Hormone-Binding Globulin (SHGB)Concentration

    Time frame: baseline & day 9

  4. Mean SHGB Concentration

    Time frame: baseline & day 9

  5. Maximum Estradiol Concentration

    Time frame: baseline & day 9

  6. Mean Estradiol Concentration

    Time frame: baseline & day 9

  7. Free T Maximum Concentration

    Time frame: baseline & day 9

    Free T normal range 4.7-18 ng/dL

  8. Free Testosterone Mean Concentration

    Time frame: baseline & day 9

    Free T normal range 4.7-18 ng/dL

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • GlaxoSmithKline

Registry information

Official study title

Pharmacokinetics of Modified Slow-Release Oral Testosterone Over 10 Days in Normal Men With Experimental Hypogonadism

Acronym: Oral T8

Important dates

Study start
2010
Primary completion
2010
Study completion
2012
First posted
Jul 22, 2010
Registry last updated
Sep 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.